康臣药业集团有限公司（康臣药业）（01681）于2026年3月2日更新披露截至2026年2月28日的股份变动月报。报告显示，公司法定股本维持5,000,000,000股，每股面值HKD 0.1，总额HKD 500,000,000，较上月无变化。
本月已发行股份数量从上月末的841,508,111股减少至841,423,111股，净减少85,000股。其中，因行使购股权计划新增发行15,000股，合计募集所得资金HKD 60,150；另于2026年1月16日完成赎回并注销100,000股普通股。期末公司确认符合香港联交所关于公众持股量的要求。
公司表示，该等股份变动已获董事会正式授权，并遵守相关上市规则及法律法规。据公告披露，月报由公司秘书高海恩签署。公司截至2月末已发行股份总数为841,423,111股，股本结构保持稳健。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.